Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Diabetes Mellitus, Type 1, Type 2
Interventions: Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more

Conditions: Type 1 Diabetes
Interventions: benfotiamine, α-lipoic acid; Dietary Supplement
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: AT247, NovoLog, Fiasp; Drug
Lead sponsor: Arecor Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type1 Diabetes Mellitus
Interventions: Dapagliflozin 5mg, Placebo Oral Tablet; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 30
States / cities: La Mesa, California • Lancaster, California • Mission Hills, California + 25 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 1
Interventions: Metabolic Challenge Admission, CGM home test; Procedure · Other
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 45 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 1
Interventions: Naloxone then placebo, Placebo then Naloxone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes
Interventions: Insupatch, Continuous glucose sensor; Device
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 44 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: Omnipod 5 System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes Mellitus, Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
Interventions: None (not interventional); Other
Lead sponsor: Levenson, David I., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: The MiniMed Paradigm® X54 System; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 16 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Escondido, California • Stanford, California • Aurora, Colorado + 2 more

Conditions: Type 1 Diabetes (T1D)
Interventions: L. johnsonii Probiotic, Placebo Capsule; Drug
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions: Dexcom G6, Dexcom G6 blinded sensor; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Placebo, INCB013739; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Chula Vista, California • The Bronx, New York • San Antonio, Texas

Conditions: Type 1 Diabetes
Interventions: Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET; Device
Lead sponsor: Sue Brown; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Blood draw; Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Duarte, California • Loma Linda, California

Conditions: Non-Insulin-Dependent Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Time Limited Eating; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Technosphere Insulin Inhalation Powder, Comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions: Hyperinsulinemic, euglycemic clamp, 20% dextrose; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years to 51 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions: Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Dapagliflozin Effects on Hypoglycemia

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

Naloxone, Hypoglycemia and Exercise

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Omnipod 5 System Compared to Pump Therapy

Long Term Follow up of Recipients of Functional Islet Allografts

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

Lactobacillus Johnsonii in Children and Adolescents With T1D

Use of CGM in Kidney Transplant Recipients

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

Time Limited Eating in Type 1 Diabetes

A 2-Month Safety Follow-Up Trial

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management